Journal of Clinical Oncology
Articles in this Issue
Palliative care utilization and acute care outcomes in metastatic prostate cancer in a safety-net health system.
e24064 Background: Patients with metastatic prostate cancer (MPCa) experience high symptom burden and frequent emergency d...
Personalized neoantigen vaccine as adjuvant therapy in high-risk postoperative esophageal carcinoma.
2511 Background: Effective adjuvant strategies for patients with esophageal carcinoma (EC) with residual pathological dise...
Exploring LEGO as a constructivist teaching tool in undergraduate and patient education of cancer survivorship topics.
e13787 Background: Cancer survivorship is a multidimensional, chronic condition requiring effective communication, interpr...
Does treatment delay matter?: Impact of time to immunotherapy on survival in extensive-stage small cell lung cancer.
8115 Background: Immune checkpoint inhibitors (ICI) combined with platinum-etoposide chemotherapy are the standard first-l...
Clinical outcomes of <i>TP53</i> -mutated myeloid neoplasms after allogeneic hematopoietic cell transplantation: A Canadian multicenter propensity score–matched analysis.
6553 Background: TP53 mutations define a biologically aggressive subset of myeloid malignancies with p...
Pathological outcomes of neoadjuvant osimertinib-based therapies versus chemotherapy in resectable EGFR-mutant NSCLC: A component network meta-analysis.
e20067 Background: Neoadjuvent chemotherapy is the current standard for resectable non–small cell lung cancer (NSCLC) yiel...
Multimodal intraoperative diagnosis and grading system integrating macroscopic images, CT imaging, and textual reports for adenocarcinoma (MaCTex) in early-stage LUAD: A multicentric diagnostic study.
8023 Background: Intraoperative frozen section (IFS) analysis is pivotal for guiding surgical strategies in stage IA lung...
Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line therapy for unresectable pleural mesothelioma: Substudy 5 of the eVOLVE-02 phase 2 study.
TPS8126 Background: Standard first-line treatment for unresectable pleural mesothelioma has evolved recently to include an...
Myoepithelial carcinoma: A National Cancer Database study of demographic and socioeconomic factors.
e22590 Background: Myoepithelial carcinoma (MECA) is a rare malignant tumor arising from myoepithelial cells and documente...
Association of pre-existing chronic kidney disease with in-hospital mortality and resource utilization among U.S. solid tumor hospitalizations: A National Inpatient Sample analysis, 2018–2022.
e23166 Background: Chronic kidney disease (CKD) is prevalent among patients with cancer and may adversely influence inpati...
Trastuzumab-deruxtecan for the management of leptomeningeal metastases from breast cancer.
e14033 Background: Targeting Human Epidermal Growth Factor Receptor 2 (HER2) with an antibody drug conjugate such as trast...
Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.
8004 Background: Lung cancer is the leading cause of cancer death in the US, yet current lung cancer screening (LCS) crite...
Characterizing the immune effects of enfortumab vedotin and pembrolizumab (EV+P) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC).
4571 Background: Enfortumab vedotin improves response and outcomes over chemotherapy in mUC, with further benefit when com...
Association of RNA-based immune gene expression with immunotherapy duration in advanced non–small cell lung cancer.
e20538 Background: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is commonly used to guide immunotherapy se...
Timeliness of care and outcomes in thymic epithelial tumors: A single-center real-world cohort in Colombia (2015–2025).
e20175 Background: Thymic epithelial tumors (TETs) are rare malignancies, and real-world evidence from Latin America remai...
<i>TP53</i> variant allele frequency as a driver of survival in <i>TP53</i> -mutated acute myeloid leukemia.
e18508 Background: TP53 -mutated AML represents a challenging subtype with only 10-15% of patients ach...
Neoadjuvant toripalimab combined with inetetamab, pertuzumab, and nab-paclitaxel in HER2-positive breast cancer (TORCH): A phase II trial.
e12658 Background: Incorporating immunotherapy into neoadjuvant therapy for HER2-positive breast cancer (BC) is an area of...
Germline HLA class II diversity as a predictor of survival selectively in MHC-silenced gliomas.
2082 Background: CD4⁺ T cell help is central to durable anti-tumour immunity and predicts response to neoantigen vaccinati...
Comprehensive clinical analysis of cervical clear cell adenocarcinoma: A real-world multicenter study.
e17525 Background: Cervical clear cell adenocarcinoma (CCAC) is a rare and aggressive malignancy for which evidence-based...
Time from diagnosis to treatment in multiple myeloma: A systematic review and meta-analysis.
e19539 Background: While delays in systemic therapy initiation adversely impact survival in various malignancies, the magn...
Global development and validation of the Lung Cancer Prevention Score (LCPS): A quantitative framework linking policy strength, incidence, and outcomes across 40 countries.
10518 Background: Lung cancer is the leading cause of cancer worldwide. Despite advances in tobacco control, national prev...
Time to treatment initiation (TTI) and survival outcomes in metastatic extrapulmonary neuroendocrine carcinoma (EP-NEC).
e16323 Background: Advanced EP-NEC are typically treated with the combination of platinum plus etoposide. Despite therapy,...
Identifying sex-specific symptom-based predictors of lung cancer risk using explainable machine learning.
e22575 Background: Lung cancer presents with a broad range of symptoms, many of which are nonspecific or atypical, contrib...
Burned-out lymph nodes in testicular cancer: A new entity in imaging and management.
e17008 Background: Germ cell tumors are the most common cancer in men between 15 and 40, with a primary testicular tumor i...
Quantifying the macroeconomic burden of tobacco-attributable cancers in 2023: Global disparities in value-of-lost-welfare (VLW) in 189 countries.
10567 Background: Tobacco use is the leading preventable cause of cancer globally, yet the macroeconomic welfare losses at...